In melanoma, imatinib has shown modest but clinically meaningful efficacy in specific biologically distinct subtypes characterized by KIT mutations or amplifications, including acral, mucosal, and chronically sun-damaged melanomas [208,209,210]. The gene discussed is KIT; the disease is melanoma.